| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93a4f4e8977e1c01dac00782d3a481d6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1018 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebd770f49df7df580a86f884b9f5e4fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3c6d5f59623b69d58feffaecc4f0c47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e11d136294772c102cd63dac00a63b37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_512626429b631d02a7b0372cdf626542 |
| publicationDate |
2020-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111116741-A |
| titleOfInvention |
Fully human neutralizing antibody for resisting H3N2 influenza virus and application thereof |
| abstract |
The invention discloses a fully human neutralizing antibody for resisting H3N2 influenza virus and application thereof. The antibody can be combined with influenza virus hemagglutinin protein (HA) with natural conformation, can prevent H3N2 subtype influenza virus from infecting susceptible cells, HAs lower immunogenicity for human bodies, can avoid antibody-mediated immune rejection reaction of human anti-mouse and other species sources, and HAs potential value for preventing and treating H3N2 subtype influenza virus infection clinically. |
| priorityDate |
2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |